However, it is important to note that STAT3 activation in various cancers may also be achieved by a number of other pathways, including downstream of receptor tyrosine kinases (particularly epidermal growth factor receptor [EGFR]), non-receptor tyrosine kinases, some serine kinases, G protein coupled receptors, Rho GTPases, cadherin engagement, and toll-like receptors [70]. The gene discussed is NTRK1; the disease is cancer.